44 articles - From Friday May 27 2022 to Friday Jun 03 2022
Guidelines, position statements, white papers, technical reviews, consensus statements, etc…
| Rheumatology (Oxford) |
meta-analyses and systematic reviews
RCT, clinical trials, retrospective studies, etc…
| Ann Rheum Dis |
Inflammatory correlates of the Patient Global Assessment of Disease Activity vary in relation to disease duration and autoantibody status in patients with rheumatoid arthritis. In the early phases of RA, particularly in autoantibody-positive patients, inflammatory variables directly correlate with the PGA across different disease activity states. The optimal cut-off values of the PGA capable of identifying absence of disease should be better explored in relation to disease duration and autoantibody status. |
Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial. Add-on low-dose prednisolone has beneficial long-term effects in senior patients with established RA, with a trade-off of 24% increase in patients with mostly non-severe AE; this suggests a favourable balance of benefit and harm. |
Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and/or anti-TNFa therapy: a placebo-controlled phase II study. ABX464 50 mg was safe, well tolerated and showed a promising efficacy. Mild-to-moderate gastrointestinal AEs led to a high drop-out rate of patients on ABX464 100 mg, which may not be a relevant dose to use. These findings warrant exploration of ABX464 at 50 mg per day or less for treating patients with RA. |
The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist. The 2021 EULAR/American College of Rheumatology points to consider represent state-of-the-art knowledge based on published data and expert opinion to guide diagnostic evaluation, treatment and monitoring of patients with CAPS, TRAPS, MKD and DIRA, and to standardise and improve care, quality of life and disease outcomes. |
| Arthritis Care Res (Hoboken) |
Evaluation of the European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in a Population Based Registry. Applying the three commonly used classification criteria to a population-based registry identified patients with SLE fulfilling only one validated definition. The most recently developed EULAR/ACR classification criteria revealed similar prevalence and incidence estimates to those previously established for the ACR and SLICC classification schemes. |
Incorporating Expected Outcomes into Clinical Decision Making for Total Knee Arthroplasty. Our results showed that clinicians would utilize expected post-operative outcomes factors in determining appropriateness for TKA. These results call for further work in this area to incorporate estimates of expected pain/function and revision outcomes into clinical practice to improve decision making for TKA. |
New and updated recommendations for the treatment of juvenile idiopathic arthritis associated uveitis and idiopathic chronic anterior uveitis. An update to the previous 2018 SHARE recommendations for the treatment of children with JIAU with the addition of CAU was created using an evidence-based consensus process. This guideline should help support clinicians to care for children and young people with chronic anterior uveitis. |
Patient Acceptable Symptom State versus Latent Class Analysis Outcome Classification: A Comparative Longitudinal Study of Knee Arthroplasty. When used for outcome classification, observed PASS scores consistently underperform relative to probabilistic latent class-derived subgroups of pain and self-rated health outcome. PASS is a weak substitute for probabilistic classification of other PROMs of KA outcome. Clinicians and researchers should rely on latent class analyses over PASS to differentiate between outcome subgroups following KA. |
| Arthritis Res Ther |
Clinical course of patients with rheumatoid arthritis who continue or discontinue biologic therapy after hospitalization for infection: a retrospective observational study. Discontinuation of biologic therapy after hospitalization for infections may result in RA flares. Continuation of biologic therapy is preferable, particularly in patients without immunodeficiency. |
Comparative analysis of the gut microbiota composition between knee osteoarthritis and Kashin-Beck disease in Northwest China. Our study provides a comprehensive landscape of the gut microbiota between OA and KBD patients and provides clues for better understanding the mechanisms underlying the pathogenesis of OA and KBD. |
Rheumatoid arthritis patients initiating rituximab with low number of previous bDMARDs failures may effectively reduce rituximab dose and experience fewer serious adverse events than patients on full dose: a 5-year cohort study. Seropositivity (OR 1.823), more than 2 previous bDMARDs failures (OR 0.428), and DAS28 |
Risk factors for the recurrence of relapsing polychondritis. Tracheal involvement, pre-treatment C-reactive protein level, and initial prednisolone monotherapy were risk factors for recurrence in patients with RP. Initial combination therapy with prednisolone and immunosuppressants may delay recurrence. |
The anterior cruciate ligament in murine post-traumatic osteoarthritis: markers and mechanics. These results demonstrate that ACL pathology and viscoelastic function are compromised in the post-trauma knee joint and reveal an important role of viscoelastic mechanical properties for ligament and potentially knee joint health. |
| Arthritis Rheumatol |
Choroid plexus-infiltrating T cells drive murine neuropsychiatric lupus. T cells, and more specifically CP-infiltrating antigen-specific T cells, contribute to the pathogenesis of NPSLE, indicating the possible therapeutic potential for modulating T cells in the development of more targeted treatments for NPSLE. |
Machine learning identifies a common signature for anti-SSA/Ro60 antibody expression across autoimmune diseases. Anti-Ro60 + patients present a specific inflammatory signature regardless of their disease suggesting that a dual therapeutic approach targeting both Ro-associated RNAs and anti-Ro60 autoantibodies should be considered. |
Risk assessment for hip and knee osteoarthritis using polygenic risk scores. The findings validated the association of PRSs across OA-definitions. Since OA is becoming frequent and primary-prevention is not commonly applicable, PRS-based risk assessment could play a role in OA-prevention. However, the PRSs utility is dependent on the setting. Further studies are needed to test the integration of genetic risk assessment in diverse health care settings. |
The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases: Cryopyrin-Associated Periodic Syndromes, Tumour Necrosis Factor Receptor-Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin-1 Receptor Antagonist. The 2021 EULAR/American College of Rheumatology points to consider represent state-of-the-art knowledge based on published data and expert opinion to guide diagnostic evaluation, treatment and monitoring of patients with CAPS, TRAPS, MKD and DIRA, and to standardise and improve care, quality of life and disease outcomes. |
The dynamics of methylation of CpG sites associated with SLE subtypes in a longitudinal cohort. In this longitudinal cohort of SLE, we identified a subset of SLE subtype associated CpGs that were stable over time and may be useful as biomarkers of disease subtypes. Another subset of SLE subtype-associated CpGs changed at a higher proportion compared to the genome-wide methylome. Additional studies are needed to understand the etiology and impact of these methylation changes in SLE-associated CpGs. |
The efficacy of short-term bridging strategies with high- and low-dose prednisolone on radiographic and clinical outcomes in active early rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Short-term glucocorticoid bridging therapy at high dose showed no benefit with regard to progression of radiographic damage at one year. |
Tofacitinib and risk of malignancy: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) Study. We did not find evidence for an increased risk of malignancy with tofacitinib, in comparison with TNFI, in RA patients treated in the real-world setting. However, our results cannot rule out a possibility of an increase in risk that may accrue with a longer treatment duration. |
| Rheumatology (Oxford) |
A new tool supporting the diagnosis of childhood-onset Behçet's disease: venous wall thickness. Increased VWT was present not only in BD patients with vascular involvement but also in those without. We suggest that VWT may be a new criterion in supporting the diagnosis of childhood BD both in definite and incomplete BD patients. |
Anti-phosphatidylserine/prothrombin antibodies and thrombosis associate positively with HLA-DRB1*13 and negatively with HLA-DRB1*03 in SLE. HLA-DRB1*13 confers risk for both anti-PS/PT and thrombotic events in lupus. The association between HLA-DRB1*13 and thrombosis is largely, but not totally, mediated through anti-PS/PT. HLA-DRB1*03 was negatively associated with aPL and positively with favorable lipid levels. Thus, HLA-DRB1*03 seems to identify a subgroup of SLE patients with reduced vascular risk. |
Cancer occurrence after SLE: effects of medication-related factors, disease-related factors, and survival from an observational study. High dosage of CTX and disease-related factors (low SLEDAI-2K, less mucocutaneous and hematologic involvement) were related factors for cancer occurrence after SLE, while no survival difference was observed. |
Development and psychometric evaluation of the PMR-Impact Scale: a new patient reported outcome measure for polymyalgia rheumatica. The PMR-IS offers researchers a new way to assess patient-reported outcomes in clinical studies of PMR. It has been developed robustly, with patient input at every stage. It has good construct validity and test re-test reliability. Further work is needed to fully establish its responsiveness and interpretability parameters and assess its real-world clinical utility. |
Impact of lung function and baseline clinical characteristics on patient-reported outcome measures in systemic sclerosis-associated interstitial lung disease. Severe SSc-ILD and major deteriorations in lung function have important impacts on HRQoL. Treatments that slow lung function decline and prevent severe SSc-ILD are important to preserve HRQoL. |
Improved outcomes in rheumatoid arthritis with obesity after a weight loss intervention: randomized trial. Obese RA patients on the diet intervention achieved weight loss. There were significant between group improvements for RAPID3, adiponectin, and leptin levels, and positive trends for DAS28 and HAQ-DI. Longer-term, larger weight loss studies are needed to validate these findings, and will allow for further investigative work to improve the clinical management of obese RA patients. |
Low incidence and transient elevation of autoantibodies post mRNA COVID-19 vaccination in inflammatory arthritis. In both health and inflammatory arthritis, the risk of autoantibody seroconversion is lower following mRNA-based immunization than following natural SARS-CoV-2 infection. Importantly, seroconversion does not correlate with self-reported IA disease flare risk, further supporting the encouragement of mRNA-based COVID-19 immunization in the IA population. |
Mosaic variants in TNFRSF1A: An emerging cause of tumor necrosis factor receptor-associated periodic syndrome. This study expands the localization of TNFRSF1A mosaic variants to the CRD1 domain. Noticeably, residues involved in germline TNFRSF1A mutational hot spots can also be involved in post-zygotic mutational events. Including our study, only four patients have been thus far reported with TNFRSF1A mosaicism highlighting the need for a high-depth NGS-based approach to avoid the misdiagnosis of TRAPS. Genetic counseling has to consider the potential occurrence of TNFRSF1A mosaic variants in germinal cells. |
Nailfold capillaroscopy: a survey of current UK practice and 'next steps' to increase uptake amongst rheumatologists. Most UK rheumatologists currently do not perform nailfold capillaroscopy on site. An internet-based nailfold capillaroscopy system, for use with low cost microscopes as well as with videocapillaroscopy, could help increase uptake of capillaroscopy and thereby facilitate early diagnosis of systemic sclerosis across the UK. |
Strong response after 4th dose of mRNA COVID-19 vaccine in autoimmune rheumatic diseases patients with poor response to inactivated vaccine. This is the largest study to provide evidence of a remarkable humoral response after the 4th dose of heterologous mRNA SARS-CoV-2 vaccination in ARD patients with poor/no-response to the 3rd dose of an inactivated vaccine. We further identified that treatment, particularly rituximab and prednisone, impaired antibody response to this additional dose. |
Plenty of the editorials are available as full text through the publisher website using the provided link
| Arthritis Rheumatol |
Letters to the editors and authors’ replies
| Arthritis Res Ther |
Zibotentan in systemic sclerosis-associated chronic kidney disease: a phase II randomised placebo-controlled trial. Zibotentan was generally well-tolerated. ZEBRA 1 did not show any effect of zibotentan on serum sVCAM-1 but was associated with numerical improvement in eGFR at 26 weeks that was more marked at 52 weeks. ZEBRA 2B suggested a feasible dose regimen for haemodialysis patients. |
| Arthritis Rheumatol |
all remaining publications eg case reports, images of the month, etc…
| Rheumatology (Oxford) |